RxDoctor Payments Data

Kristina Clarisse Doble

Nurse Practitioner · Las Vegas, NVNPI 1326587155

Payments from drug & device makers

$1,769in general payments, 2019–2025

Across 45 payments — averaging $39.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$733
  • Ardelyx, Inc.$270
  • Vifor Pharma, Inc.$170
  • Akebia Therapeutics Inc$147
  • Novo Nordisk$118
  • AstraZeneca$117
  • plus $214 from 6 others

What the payments were for

  • Food & beverage$1,769100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,769 in reported general payments places this provider in the 80th percentile of 933 nurse practitioner providers in Nevada.

See all nurse practitioner providers in Nevada

Medicare billing

Part B allowed, 2024
$55,537
Medicare patients
130
Services billed
616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl115$343,221
VelphoroSucroferric Oxyhydroxide126$318,164
AuryxiaFerric Citrate40$61,123
VeltassaPatiromer Calcium Sorbitex33$39,175
Sevelamer Carbonate279$37,113
RenvelaSevelamer Carbonate20$28,791
Lanthanum Carbonate33$27,912
LokelmaSodium Zirconium Cyclosilicate27$16,718
Midodrine Hcl48$1,758
Hydralazine Hcl88$1,696
Amlodipine Besylate107$983
Doxazosin Mesylate25$873
Carvedilol79$809
Clonidine Hcl43$787
Lidocaine-PrilocaineLidocaine/Prilocaine22$756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$733$318,164126 claims
Akebia Therapeutics IncAuryxia$147$61,12340 claims
AstraZenecaLokelma$117$16,71827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 933 nurse practitioner providers in Nevada.

Other nurse practitioner in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →